Vision Innovation Partners Appoints Dr. Brad Foster as Chief Medical and Strategy Officer

ANNAPOLIS, Md.--(BUSINESS WIRE)--Vision Innovation Partners (“VIP”), a leading Mid-Atlantic eye care platform with 69 locations, today announced that it has appointed Dr. Brad Foster as Chief Medical and Strategy Officer.

The Chief Medical and Strategy Officer role is a new leadership position within VIP and is intended to improve patient outcomes and clinical quality across the company’s platform. As part of his responsibilities, Dr. Foster will work closely with VIP's physicians to establish clinical performance benchmarks and drive greater accountability through standardized processes.

Chris Moore, CEO of Vision Innovation Partners, said, “We are pleased to welcome Dr. Foster to our leadership team. His appointment reflects our steadfast commitment to providing leading clinical practitioners with the support and comprehensive suite of services required to help them take eye care to the next level. Throughout his career, Dr. Foster has thrived at the intersection of clinical excellence, operational efficiency, and strategic growth. His proven ability to optimize multi-site operations and shape scalable clinical strategies will help us enhance and expand our suite of services and capabilities as we continue our mission to serve as the premier vision care provider throughout the Mid-Atlantic region.”

Dr. Foster is a highly accomplished and distinguished physician and leader who possesses extensive experience leading innovative, transformational change across ophthalmology, multi-site surgical and medical practices. As Founder and Managing Partner of New England Retina Consultants, Dr. Foster spent more than 20 years overseeing all aspects of practice management, including talent acquisition, financial operations, compliance oversight, and strategic risk mitigation, while maintaining an active clinical practice. During this time, he also established a retina research institute that served as a key site for conducting major clinical trials, increasing institutional visibility and advancing access to cutting-edge therapies. Dr. Foster also excelled as Co-Founder and Chief Medical Officer of Millennium Vision Partners, where he directed strategic outreach and engagement with physician groups, aligning clinical and operational goals to support long-term integration and value creation, and as Chief Medical Officer at Ascend Vision Partners, where he improved infection control practices, right-sized staffing models, implemented enterprise-wide protocols and enhanced utilization management across surgical centers.

“I am excited to join VIP as I embark on the next phase of an incredibly fulfilling career,” said Dr. Foster. “Working with the best and brightest minds in ophthalmology that are at the forefront of providing best-in-class eye care services was a critical factor when considering where I could add the most value. VIP is an optimal fit given its relentless focus on providing great patient outcomes and experiences. I look forward to working closely with Chris and having the opportunity to help drive further value across the company’s platform.”

Dr. Foster currently serves on the Board of Advisors of Blue Clay Health, a private medical advisory service dedicated to providing continuous clarity and safety for individuals navigating complex medical conditions. He received his B.S. in Neurobiology and Behavior from Cornell University, his MD from the Joan and Sanford I. Weill Medical College of Cornell University, and his MHA from Cornell University. Dr. Foster completed his fellowship at Mass Eye and Ear, a member of Mass General Brigham and a teaching hospital of Harvard Medical School.

VIP is backed by Gryphon Investors, a leading middle-market private investment firm.

About Vision Innovation Partners
Founded in 2017 and headquartered in Annapolis, MD, VIP supports the Mid-Atlantic’s premier ophthalmology practices and surgery centers through good people, expert leadership, the sharing of best practices and the backing of Gryphon Investors, a leading middle-market private investment firm. VIP’s managed practices offer a comprehensive range of services, including routine eye exams and LASIK surgery as well as treatment for cataracts, glaucoma, macular degeneration, and other ocular diseases. The Company is among the region’s leading managed services platforms for ophthalmology providers, with over 150 providers and a footprint that includes 69 locations including 12 surgery centers across Maryland, Washington, D.C., Virginia, Pennsylvania, and Delaware.

About Gryphon Investors
Gryphon Investors is a leading middle-market private investment firm focused on growing competitively-advantaged companies in the Business Services, Consumer, Healthcare, Industrial Growth, Software, and Technology Solutions & Services sectors. With more than $10 billion of assets under management, Gryphon prioritizes investments in which it can form strong partnerships with founders, owners, and management teams to accelerate the building of leading, high-quality companies and generate enduring value through its integrated deal and operations business model. Since 1999, Gryphon’s highly-differentiated model integrates its well-proven Operations Resources Group, which is led by full-time, Gryphon senior operating executives with general management, artificial intelligence, human capital acquisition and development, acquisition due diligence and integration planning, treasury, finance, and accounting expertise. Gryphon’s three core investment strategies include its Flagship, Heritage, and Junior Capital strategies, each with dedicated funds of capital. The Flagship and Heritage strategies target equity investments of $50 million to $500 million per portfolio company. The Junior Capital strategy targets investments of $10 million to $25 million in junior securities of credit facilities, arranged by leading middle-market lenders, in both Gryphon-controlled companies, as well as in other private equity-backed companies operating in Gryphon’s targeted investment sectors.